+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Endometrial Cancer Treatment Market - Global Forecast 2026-2032- Product Image
Endometrial Cancer Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Endometrial Cancer Treatment Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888365
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Endometrial Cancer Treatment Market is projected to reach USD 9.93 Billion in 2026. It is expected to continue growing at a CAGR of 7.69%, reaching USD 15.77 Billion by 2032.

Endometrial Cancer Treatment: Executive Overview

Endometrial cancer treatment is evolving through improved disease classification, molecular profiling, surgical techniques, radiation delivery, systemic therapies, and coordinated survivorship care. Clinical decisions increasingly reflect stage, histology, grade, molecular characteristics, patient fitness, fertility considerations, and treatment goals. The field spans prevention and early detection research, surgery, radiotherapy, chemotherapy, hormone therapy, immunotherapy, targeted approaches, and supportive care.

Treatment Is Shifting Toward Risk-Adapted, Molecularly Informed Care

The treatment landscape is moving beyond anatomy alone toward integrated clinicopathologic and molecular risk assessment. More precise stratification can support decisions about the intensity of surgery, adjuvant radiation, systemic therapy, and follow-up. Minimally invasive surgery, sentinel lymph-node assessment, image-guided radiotherapy, and multidisciplinary tumor boards are reinforcing efforts to reduce avoidable morbidity while preserving disease control. Persistent challenges include treatment access, clinical trial participation, toxicity management, and variation in guideline implementation.

Artificial Intelligence Strengthens Diagnosis, Planning, and Patient Management

Artificial intelligence is being applied across pathology image analysis, radiology interpretation, recurrence-risk assessment, treatment planning, and operational workflows. Its potential value includes improving consistency in tumor classification, identifying clinically relevant patterns, supporting radiation contouring, and helping teams prioritize follow-up. However, reliable deployment requires representative validation datasets, transparent performance assessment, clinician oversight, cybersecurity, privacy safeguards, and monitoring for bias. AI should complement-not replace-pathologists, radiologists, oncologists, surgeons, and patients in shared decisions.

Regional Insights: Access and Care Models Differ Across Six Geographies

North America generally combines advanced diagnostic infrastructure, broad access to multidisciplinary oncology, and active clinical research, although affordability and care disparities remain important concerns. Europe benefits from established cancer networks and guideline-based practice, while differences in reimbursement, referral pathways, and molecular testing affect implementation. Asia-Pacific contains highly diverse health systems, ranging from advanced specialist centers to areas with limited oncology capacity. Latin America faces uneven access to pathology, radiotherapy, medicines, and specialist care. The Middle East is expanding oncology infrastructure but continues to experience differences between major urban centers and underserved populations. Africa faces substantial constraints in screening awareness, diagnosis, pathology, surgery, radiotherapy, medicines, and specialist workforce capacity, making referral systems and health-system strengthening especially important.

Group Insights: Regional Blocs Shape Coordination and Access

ASEAN countries show varied oncology capacity and opportunities for shared procurement, workforce development, referral networks, and harmonized clinical guidance. BRICS members have substantial scientific and manufacturing capabilities but marked differences in access, infrastructure, and regional equity. The European Union supports cross-border research, regulatory coordination, and efforts to reduce disparities, while national reimbursement decisions remain influential. G7 countries typically possess mature cancer systems and research ecosystems, yet aging populations, affordability, and equitable access remain priorities. GCC states are investing in specialist infrastructure, precision diagnostics, and coordinated care, with continued attention to workforce development and prevention. NATO members represent diverse health systems, making resilience, supply continuity, and collaborative medical research relevant considerations.

Country Insights: National Systems Influence Treatment Pathways

Australia combines specialist oncology services with geographic access challenges, particularly outside major cities. Brazil has advanced centers alongside pronounced regional disparities in diagnosis and treatment. Canada benefits from coordinated public cancer systems but faces geographic and waiting-time pressures. China is expanding specialized oncology capacity and molecular diagnostics across a highly varied health landscape. France, Germany, Italy, and Spain have established clinical networks, with differences in reimbursement, referral practices, and regional service availability. India combines leading tertiary centers with major gaps in affordability, workforce, and rural access. Japan and South Korea have sophisticated cancer systems, aging-population pressures, and strong interest in precision care. Mexico continues to address uneven access to pathology, radiotherapy, and specialist services. Russia has substantial urban oncology capacity but faces geographic and infrastructure variation. The United Kingdom has structured national guidance and research capabilities, alongside capacity and pathway pressures. The United States offers extensive specialist and clinical-trial access, while insurance coverage, treatment cost, and disparities influence care.

Priorities for Leaders: Integrate Precision, Access, and Patient-Centered Delivery

Industry leaders should align product development and service models with molecularly defined patient needs, clinically meaningful outcomes, and real-world usability. Partnerships with pathology laboratories, health systems, patient organizations, and regulators can improve testing pathways and evidence generation. Investments should prioritize interoperable data, validated AI tools, toxicity monitoring, survivorship support, and equitable access programs. Organizations should also strengthen trial diversity, develop implementation plans for lower-resource settings, secure supply chains, and measure outcomes across demographic and geographic groups. Clear communication about benefits, risks, uncertainty, and treatment alternatives is essential for shared decision-making.

Research Methodology: Evidence-Based Synthesis of Treatment Developments

This executive summary uses a structured review framework for endometrial cancer treatment, emphasizing authoritative clinical guidelines, peer-reviewed research, regulatory and health-system publications, and established epidemiologic and implementation evidence. Findings are organized around therapeutic innovation, diagnostics, AI applications, regional health-system conditions, and practical leadership priorities. Claims are screened for relevance and consistency, while country and bloc observations are presented qualitatively to avoid unsupported quantification. Because treatment standards and evidence evolve, conclusions should be interpreted alongside current local guidelines, regulatory decisions, and multidisciplinary clinical judgment.

Conclusion: Better Outcomes Depend on Precision and System Capacity

Endometrial cancer treatment is becoming more individualized through integrated pathology, molecular classification, minimally invasive procedures, modern radiotherapy, systemic innovation, and data-enabled care. The benefits of these advances will depend on dependable diagnostic pathways, trained multidisciplinary teams, equitable access, responsible AI governance, and sustained research. Leaders who connect therapeutic innovation with implementation, affordability, patient experience, and regional health-system realities will be best positioned to improve the consistency and quality of care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Endometrial Cancer Treatment Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Combination Therapy
7.4. Hormone Therapy
7.5. Immunotherapy
7.6. Radiation Therapy
7.7. Surgery
7.8. Targeted Therapy
8. Endometrial Cancer Treatment Market, by Drug Class
8.1. Introduction
8.2. Antiangiogenic Therapy
8.3. Chemotherapeutic Agents
8.3.1. Platinum Based Agents
8.3.2. Taxanes
8.4. Hormonal Therapy
8.4.1. Aromatase Inhibitors
8.4.2. Progestins
8.5. Immunotherapy
8.5.1. CTLA-4 Inhibitors
8.5.2. PD-1 Inhibitors
8.6. Targeted Therapy
8.6.1. MTOR Inhibitors
8.6.2. PARP Inhibitors
8.6.3. Tyrosine Kinase Inhibitors
9. Endometrial Cancer Treatment Market, by Mode Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Endometrial Cancer Treatment Market, by Administration Setting
10.1. Introduction
10.2. Ambulatory Care
10.3. Hospital Inpatient
10.4. Hospital Outpatient
11. Endometrial Cancer Treatment Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Endometrial Cancer Treatment Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Endometrial Cancer Treatment Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Amgen Inc.
15.3. AstraZeneca PLC
15.4. BioNTech SE
15.5. Boehringer Ingelheim International GmbH
15.6. Bristol-Myers Squibb Company
15.7. Eisai Co., Ltd.
15.8. Exelixis, Inc.
15.9. F. Hoffmann-La Roche Ltd
15.10. Genmab A/S
15.11. GSK plc
15.12. ImmunoGen, Inc.
15.13. Johnson & Johnson
15.14. Karyopharm Therapeutics Inc.
15.15. Merck & Co., Inc.
15.16. Novartis AG
15.17. Pfizer Inc.
15.18. Regeneron Pharmaceuticals, Inc.
15.19. Syndax Pharmaceuticals, Inc.
15.20. Takeda Pharmaceutical Company Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Endometrial Cancer Treatment Market, Years Considered for the Study
FIGURE 2. Global Endometrial Cancer Treatment Market, Research Design
FIGURE 3. Global Endometrial Cancer Treatment Market, Research Framework
FIGURE 4. Global Endometrial Cancer Treatment Market, Data Triangulation
FIGURE 5. Global Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Endometrial Cancer Treatment Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Endometrial Cancer Treatment Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Endometrial Cancer Treatment Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 9. Global Endometrial Cancer Treatment Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Endometrial Cancer Treatment Market Size, by Administration Setting, 2025 vs 2032 (%)
FIGURE 13. Global Endometrial Cancer Treatment Market Size, by Administration Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Endometrial Cancer Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Endometrial Cancer Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Endometrial Cancer Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Endometrial Cancer Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Endometrial Cancer Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Endometrial Cancer Treatment Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Endometrial Cancer Treatment Market Segmentation & Coverage
TABLE 2. Global Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Chemotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Chemotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Chemotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Hormone Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Hormone Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Hormone Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Radiation Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Radiation Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Radiation Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Surgery Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Surgery Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Surgery Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Targeted Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Targeted Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Targeted Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 26. Global Antiangiogenic Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Antiangiogenic Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Antiangiogenic Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Chemotherapeutic Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Chemotherapeutic Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Chemotherapeutic Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Platinum Based Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Platinum Based Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Platinum Based Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Taxanes Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Taxanes Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Taxanes Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Hormonal Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hormonal Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hormonal Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Aromatase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Aromatase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Aromatase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Progestins Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Progestins Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Progestins Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global CTLA-4 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global CTLA-4 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global CTLA-4 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global PD-1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global PD-1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global PD-1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Targeted Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Targeted Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Targeted Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global MTOR Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global MTOR Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global MTOR Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global PARP Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global PARP Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global PARP Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Tyrosine Kinase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Tyrosine Kinase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Tyrosine Kinase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 69. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 76. Global Ambulatory Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Ambulatory Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Ambulatory Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Hospital Inpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Hospital Inpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Hospital Inpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Hospital Outpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Hospital Outpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Hospital Outpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Endometrial Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Endometrial Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 95. North America Endometrial Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. North America Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 97. North America Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 98. North America Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 99. North America Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 100. North America Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 101. North America Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 102. North America Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 103. North America Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 104. Latin America Endometrial Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Latin America Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 106. Latin America Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 107. Latin America Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 108. Latin America Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 109. Latin America Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 110. Latin America Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 111. Latin America Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 112. Latin America Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 113. Europe Endometrial Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Europe Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 115. Europe Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 116. Europe Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 117. Europe Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 118. Europe Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 119. Europe Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 120. Europe Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 121. Europe Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 122. Middle East Endometrial Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Middle East Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 124. Middle East Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 125. Middle East Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 126. Middle East Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 127. Middle East Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 128. Middle East Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 129. Middle East Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 130. Middle East Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 131. Africa Endometrial Cancer Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Africa Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 133. Africa Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 134. Africa Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 135. Africa Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 136. Africa Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 137. Africa Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 138. Africa Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 139. Africa Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 140. Global Endometrial Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. ASEAN Endometrial Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. ASEAN Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 143. ASEAN Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 144. ASEAN Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 145. ASEAN Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 146. ASEAN Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 147. ASEAN Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 148. ASEAN Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 149. ASEAN Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 150. GCC Endometrial Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. GCC Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 152. GCC Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 153. GCC Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 154. GCC Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 155. GCC Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 156. GCC Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 157. GCC Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 158. GCC Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 159. European Union Endometrial Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. European Union Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 161. European Union Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 162. European Union Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 163. European Union Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 164. European Union Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 165. European Union Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 166. European Union Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 167. European Union Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 168. BRICS Endometrial Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. BRICS Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 170. BRICS Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 171. BRICS Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 172. BRICS Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 173. BRICS Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 174. BRICS Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 175. BRICS Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 176. BRICS Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 177. G7 Endometrial Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. G7 Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 179. G7 Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 180. G7 Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 181. G7 Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 182. G7 Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 183. G7 Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 184. G7 Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 185. G7 Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 186. NATO Endometrial Cancer Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. NATO Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 188. NATO Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 189. NATO Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 190. NATO Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 191. NATO Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 192. NATO Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 193. NATO Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 194. NATO Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 195. Global Endometrial Cancer Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 196. United States Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 197. United States Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 198. United States Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 199. United States Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 200. United States Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 201. United States Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 202. United States Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 203. United States Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 204. United States Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 205. Canada Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 206. Canada Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 207. Canada Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 208. Canada Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 209. Canada Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 210. Canada Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 211. Canada Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 212. Canada Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 213. Canada Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 214. Mexico Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 215. Mexico Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 216. Mexico Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 217. Mexico Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 218. Mexico Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 219. Mexico Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 220. Mexico Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 221. Mexico Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 222. Mexico Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 223. Brazil Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 224. Brazil Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 225. Brazil Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 226. Brazil Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 227. Brazil Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 228. Brazil Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 229. Brazil Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 230. Brazil Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 231. Brazil Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 232. United Kingdom Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 233. United Kingdom Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 234. United Kingdom Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 235. United Kingdom Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 236. United Kingdom Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 237. United Kingdom Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 238. United Kingdom Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 239. United Kingdom Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 240. United Kingdom Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 241. Germany Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 242. Germany Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 243. Germany Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 244. Germany Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 245. Germany Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 246. Germany Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 247. Germany Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 248. Germany Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 249. Germany Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 250. France Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 251. France Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 252. France Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 253. France Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 254. France Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 255. France Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 256. France Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 257. France Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 258. France Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 259. Russia Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 260. Russia Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 261. Russia Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 262. Russia Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 263. Russia Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 264. Russia Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 265. Russia Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 266. Russia Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 267. Russia Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 268. Italy Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 269. Italy Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 270. Italy Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 271. Italy Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 272. Italy Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 273. Italy Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 274. Italy Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 275. Italy Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 276. Italy Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 277. Spain Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 278. Spain Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 279. Spain Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 280. Spain Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 281. Spain Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 282. Spain Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 283. Spain Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 284. Spain Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 285. Spain Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 286. China Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 287. China Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 288. China Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 289. China Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 290. China Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 291. China Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 292. China Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 293. China Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 294. China Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 295. India Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 296. India Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 297. India Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 298. India Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 299. India Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 300. India Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 301. India Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 302. India Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 303. India Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 304. Japan Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 305. Japan Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 306. Japan Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 307. Japan Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 308. Japan Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 309. Japan Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 310. Japan Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 311. Japan Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 312. Japan Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 313. Australia Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 314. Australia Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 315. Australia Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 316. Australia Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 317. Australia Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 318. Australia Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 319. Australia Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 320. Australia Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 321. Australia Endometrial Cancer Treatment Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 322. South Korea Endometrial Cancer Treatment Market Size, 2017-2032 (USD Million)
TABLE 323. South Korea Endometrial Cancer Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 324. South Korea Endometrial Cancer Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 325. South Korea Endometrial Cancer Treatment Market Size, by Chemotherapeutic Agents, 2017-2032 (USD Million)
TABLE 326. South Korea Endometrial Cancer Treatment Market Size, by Hormonal Therapy, 2017-2032 (USD Million)
TABLE 327. South Korea Endometrial Cancer Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 328. South Korea Endometrial Cancer Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 329. South Korea Endometrial Cancer Treatment Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 330. South Korea Endo

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GSK plc
  • ImmunoGen, Inc.
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Syndax Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Endometrial Cancer Treatment - Global Strategic Business Report - Product Image

Endometrial Cancer Treatment - Global Strategic Business Report

  • Report
  • 176 Pages
  • Global
From
Endometrial Cancer Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Endometrial Cancer Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Endometrial Cancer Treatment Market Report 2026 - Product Image

Endometrial Cancer Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Endometrial Cancer - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Endometrial Cancer - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Uterine Cancer Therapeutics & Diagnostics Market - Global Forecast 2026-2032 - Product Image

Uterine Cancer Therapeutics & Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From

About the Endometrial Cancer Drug Market

The Endometrial Cancer Drug market is a subset of the Uterine Cancer Drugs market, which is composed of drugs used to treat endometrial cancer, a type of cancer that affects the lining of the uterus. Endometrial cancer drugs are typically used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy is used to reduce the amount of estrogen in the body, while chemotherapy is used to kill cancer cells. Targeted therapy is used to target specific cancer cells, while immunotherapy is used to boost the body's immune system to fight cancer. Some companies in the Endometrial Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.